Neurocrine Biosciences
NBIX
#1452
Rank
S$16.01 B
Marketcap
$158.21
Share price
-4.00%
Change (1 day)
4.34%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.67

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $2.63. In 2022 the company made an earnings per share (EPS) of $2.16 an increase over its 2021 EPS that were of $1.27.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.6723.86%
2022$2.1669.47%
2021$1.27-78.21%
2020$5.85990%
2019$0.5481.82%
2018$0.30-113.5%
2017-$2.190.62%
2016-$2.1757.28%
2015-$1.3825.61%
2014-$1.1018.84%
2013-$0.93-1085.71%
2012$0.09388-89.71%
2011$0.91-500%
2010-$0.23-86.92%
2009-$1.74-43.48%
2008-$3.08-57.8%
2007-$7.3192.58%
2006-$3.80371.67%
2005-$0.80-52.76%
2004-$1.7036.56%
2003-$1.25-70%
2002-$4.16118.31%
2001-$1.908.4%
2000-$1.7648.86%
1999-$1.18-20%
1998-$1.48-479.31%
1997$0.39

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$2.80 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.74-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$3.97-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$7.28 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$4.94 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.49-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.63-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.06-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA